Incyte to Market Galapagos Adenoviral Expression Platform

Nov 14, 2000

NEW YORK, Nov 14 – Incyte has signed a three-year agreement with Galapagos Genomics to develop and market an adenoviral gene expression platform, the companies announced Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

New Products Posted to GenomeWeb This Week: PerkinElmer, Agilent, Desktop Genetics, More
Whole-Genome Sequencing Can Yield Diagnoses for NICU Cases
Majority of Genetics Professionals Supports Human Gene Editing, Stanford Survey Finds
Genomic Vision, AmCare Genomics Ink Deal to Distribute Muscular Dystrophy Assay in China
US Air Force Studying Impact of Exome Sequencing in Routine Care
Evolutionary Analysis Reveals Number, Nature of Mutations Under Positive Selection in Cancer

The Scan

Second One From Kite

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Worth the Price?

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Beyond Counting Tree Rings

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

This Week in Nature

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.

Main menu